search
Back to results

A Non-Traumatic Binder for Temporary Abdominal Wall Closure (ABRO)

Primary Purpose

Abdominal Trauma, Abdominal Injury, Abdominal Infection

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Experimental: ABRO™ Binder Arm
Placebo Comparator: Usual Care
Sponsored by
Unity Health Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abdominal Trauma focused on measuring Abdominal trauma/injury, Abdominal sepsis/infection, Open Abdomen, Abdominal binder, Abthera, VAC, ABRO

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Mechanically ventilated patients, managed with the OA strategy.
  • 16 years of age or older

Exclusion Criteria:

  • Patients who are pregnant
  • Loss of any portion of the abdominal wall that could preclude primary closure
  • Burn patients
  • BMI greater than 40 kg/m2

Sites / Locations

  • Royal Columbian Hospital
  • Vancouver General Hospital
  • QEII Health Sciences Center
  • St. Michael's HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Usual Care

Device: ABRO™Binder Arm

Arm Description

The current approach for temporary coverage of abdomen is called "vacuum assisted techniques (VAT)". This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.

Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™

Outcomes

Primary Outcome Measures

Total number of patients who experience complete abdominal closure with sutures without the use of mesh and/or component separation.
The primary outcome will measure the total number of patients who experience complete abdominal closure with sutures without the use of mesh and/or component separation.

Secondary Outcome Measures

Full Information

First Posted
November 22, 2017
Last Updated
March 8, 2022
Sponsor
Unity Health Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT03815370
Brief Title
A Non-Traumatic Binder for Temporary Abdominal Wall Closure
Acronym
ABRO
Official Title
A Non-Traumatic Binder for Temporary Abdominal Wall Closure (ABRO) Multicentre Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2019 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
March 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Unity Health Toronto

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
At the end of most abdominal operations, the fascial layer is closed by stitching edges of the wound together. However, because of logistic and/or technical reasons or the patient's critical condition, the surgeon is forced to leave the abdomen open. The current approach for temporary coverage of abdomen is vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site. Although this is the most successful and commonly used procedure, there are some limitations to this method. For example, VAT have little effect on preventing lateral movement of the wound edges. Therefore, VAT it is not the ideal procedure in aiding surgeons to closed the abdomen. The purpose of this study is to compare usual care (vacuum or non-vacuum methods for temporary coverage of the OA) versus usual care plus a novel new abdominal binder device called ABRO™ that may aid in the closure of patients who undergo open abdomen closure procedures.
Detailed Description
At the end of most abdominal operations the fascial layer is closed primarily. However, because of logistic, physiological and or anatomical reasons, the surgeon needs to leave the abdomen open. In those circumstances, attempts to close the abdomen could potentially lead to unnecessary damage to the abdominal wall fascia, intra-abdominal hypertension, abdominal compartment syndrome and abdominal wall dehiscence post-operatively. The use of the "open abdomen" (OA) in the post-operative period is not uncommon. Currently, three important trends provide grounds for increased use of this surgical strategy: Lifesaving surgical procedures in severely injured trauma patients. Surgical procedures performed in patients with non-traumatic surgical emergencies Abdominal catastrophes in elderly patients with pre-existing medical conditions. The OA is not a new strategy in the surgeon's armamentarium. A recent publication retrieved more than 1300 articles over the last 25 years relative to the management of the OA, published in the English language.5 However, the precise incidence of the OA is unknown. Nonetheless, hospitals around the world, particularly those that receive trauma victims, have an OA rate of 1-5% among their most critically ill surgical patients. This lifesaving surgical strategy does not come without a price. The mortality rate of an OA is approximately 30%. There is also a wide range of complications linked to this procedure. The OA exposes large surface area of the body to the environment increasing fluid losses. Maintenance of adequate fluid and nutritional status of the patient are challenging in this setting. Furthermore, the exposed abdominal cavity also poses greater risk for local contamination from external sources that could ultimately result in sepsis. Impaired abdominal wall function interferes with ventilatory mechanics. Consequently, patients with OA are prone to respiratory complications. However, the most dreaded complication of an OA is the formation of an enteroatmospheric fistula (EF). The incidence of EF is approximately 11-15%, and increases with time. Patients who have an OA for more than 8 days have an incidence of ECF as high as 25%, caused mainly by damage to the exposed bowel. Management this complication is extremely challenging, very costly, and carries a mortality rate of 36-64%. In consideration of the foregoing considerations, early closure of the OA is undoubtedly the most effective way to prevent complications linked to this lifesaving surgical strategy. One of the most important barriers to early closure of the OA is lateral retraction of the fascial wound edges. Retraction presents as early as three days post-operatively, involves all layers of the abdominal wall and ultimately results in loss of domain. Moreover, generalized edema, atrophy and contraction of the abdominal muscles also contribute to a progressively larger defect in the fascia.Another important problem is "buckling" of the rectus abdominal muscles resulting in a "diamond" shape defect in the fascial that is very difficult to close. Management of the OA prior to definitive closure call for temporary closure techniques. The three main objectives of temporary closure techniques are to prevent injury to the bowel, manage fluid loss from the abdominal cavity, and ultimately to facilitate primary closure. Early closure is dependent on technical factors and patients' underlying clinical condition. Despite all efforts to facilitate primary fascial closure, this condition is successfully achieved only in approximately 60% of the cases. Currently, vacuum assisted techniques (VAT) are the most frequent, and arguably the most efficacious method for temporary coverage of the OA. Furthermore, VAT are particularly useful in the management of edema fluid, gastrointestinal and peritoneal secretions. Despite these important benefits, VAT provide minimal support to prevent lateral retraction of the abdominal wall fascial edges. Indeed, vacuum closure devices are not able to brace the abdominal wall and prevent lateralization of the rectus muscles even with maximum negative pressure. Moreover, excessive negative pressure applied to the abdominal cavity could potentially provoke severe injury to the intra-abdominal organs and interfere with physiologic functions. Devices applied surgically to the abdominal wall are more effective in preventing lateral retraction of the fascial edges. However, these devices are stitched through the skin, subcutaneous tissue, muscle, and fascial layers. These stitches frequently cut through the aforementioned tissues because of the high pressure at the suture sites produced by counteracting forces. The resulting wounds encompass all layers of the abdominal wall including the fascia. Another important drawback of devices that require a surgical procedure for application is the need for frequent trips to operating room for assessment and potential adjustments. Furthermore, technical limitations inherit to surgically applied temporary closure devices result in undesirable delay for the initial placement. A recent report showed that the mean time from the primary operation to placement of the temporary closure device was 9.5 days.16 This is dangerously close to the critical period of EF formation and loss of abdominal domain. Interim analysis of the data obtained from the initial randomized clinical trial to investigate the original prototype of the non-traumatic binder for abdominal wall closure (ABROTM) described in this protocol showed promising results (n=20 patients). The utilization of the original prototype of the ABROTM device resulted in 80% primary fascial closure rate compared to only 50% when VAT alone was employed. All patients (n=10) subjected to the application of the original prototype of the ABROTM device had their abdomen closed by primary fascial suture, without component separation or mesh. The ABROTM prototype resulted in greater than 65% reduction in the maximum width and the area of the fascial defects at 4 ± 1 days post-operative, whereas VAT alone resulted in a 5% increase. Moreover, interim analysis of the data showed that there were no complications from the use of the prototype of the ABROTM device. Therefore, it is anticipated that the use of the new ABROTM device in the proposed multicentre randomized controlled trial may have several advantages compared to preexisting methods for closure of the OA

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Trauma, Abdominal Injury, Abdominal Infection, Abdominal Sepsis, Abdominal Abscess, Abdominal Aneurysm, Abdominal Compartment Syndrome, Peritonitis
Keywords
Abdominal trauma/injury, Abdominal sepsis/infection, Open Abdomen, Abdominal binder, Abthera, VAC, ABRO

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The purpose of this study is to compare usual care (vacuum or non-vacuum methods for temporary coverage of the OA) versus usual care plus the new abdominal binder device called ABRO™.
Masking
None (Open Label)
Masking Description
It is impossible for the participant or anyone within the patients circle of care to be blinded in this study, as it is clear if the abdominal binder is on the participant or not. There is no way to blind in this interventional study.
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Usual Care
Arm Type
Placebo Comparator
Arm Description
The current approach for temporary coverage of abdomen is called "vacuum assisted techniques (VAT)". This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.
Arm Title
Device: ABRO™Binder Arm
Arm Type
Experimental
Arm Description
Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
Intervention Type
Device
Intervention Name(s)
Experimental: ABRO™ Binder Arm
Intervention Description
ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
Intervention Type
Device
Intervention Name(s)
Placebo Comparator: Usual Care
Intervention Description
The current approach for temporary coverage of abdomen is called "vacuum assisted techniques (VAT)". This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.
Primary Outcome Measure Information:
Title
Total number of patients who experience complete abdominal closure with sutures without the use of mesh and/or component separation.
Description
The primary outcome will measure the total number of patients who experience complete abdominal closure with sutures without the use of mesh and/or component separation.
Time Frame
Outcome measures will record when closure of the abdomen takes place up to 11 days after randomization.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Mechanically ventilated patients, managed with the OA strategy. 16 years of age or older Exclusion Criteria: Patients who are pregnant Loss of any portion of the abdominal wall that could preclude primary closure Burn patients BMI greater than 40 kg/m2
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Joao Rezende, MD
Phone
416-864-5284
Email
Rezendenetoj@smh.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Sandy Trpcic
Phone
416-864-6060
Ext
7131
Email
TrpcicS@smh.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joao Rezende-Neto, MD
Organizational Affiliation
Unity Health Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Columbian Hospital
City
New Westminster
State/Province
British Columbia
ZIP/Postal Code
V3L3W7
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vesna Ivkov
Email
vesna.ivkov@fraserhealth.ca
First Name & Middle Initial & Last Name & Degree
Michelle Goecke, MD, MSc
Facility Name
Vancouver General Hospital
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z1M9
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vahid Mehrnoush
Email
vahid.mehrnoush@vch.ca
First Name & Middle Initial & Last Name & Degree
Emilie Joos, MDCM
First Name & Middle Initial & Last Name & Degree
Naisan Garraway, CD, MD
Facility Name
QEII Health Sciences Center
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H3G1
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lisa Julien
Email
lisa.julien@nshealth.ca
First Name & Middle Initial & Last Name & Degree
Samuel Minor, MD
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B1W8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sandy Trpcic
Phone
416-864-6060
Ext
7131
Email
trpcics@smh.ca
First Name & Middle Initial & Last Name & Degree
Joao Rezende-Neto, MD, PhD

12. IPD Sharing Statement

Learn more about this trial

A Non-Traumatic Binder for Temporary Abdominal Wall Closure

We'll reach out to this number within 24 hrs